Safety of anti-tumour necrosis factor-α agents in psoriasis patients who were chronic hepatitis B carriers: A retrospective report of seven patients and brief review of the literature

Journal of the European Academy of Dermatology and Venereology

Volumn 25, Issue 4, 2011, Pages 471-474

  Fotiadou, C ^a   Lazaridou, E ^a   Ioannides, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

adalimumab; chronic hepatitis B; etanercept; infliximab; lamivudine; psoriasis

Indexed keywords

ADALIMUMAB; ETANERCEPT; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COMORBIDITY; DRUG SAFETY; FEMALE; FOLLOW UP; HEPATITIS B; HUMAN; LIVER FUNCTION TEST; MALE; MEDICAL RECORD; OUTPATIENT; PRIORITY JOURNAL; PSORIASIS; RETROSPECTIVE STUDY; VIRUS LOAD; VIRUS REACTIVATION;

ADULT; AGED; CARRIER STATE; FEMALE; HEPATITIS B, CHRONIC; HUMANS; MALE; MIDDLE AGED; PSORIASIS; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 79952412110     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/j.1468-3083.2010.03754.x     Document Type: Article

References (20)

1. Schafer T,. Epidemiology of psoriasis. Review and the German prospective. Dermatology 2006; 212: 327-337.
2. Nickoloff BJ,. The cytokine network in psoriasis. Arch Dermatol 1991; 127: 871-884.
3. Herbein G, OBrien WA,. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000; 223: 241-257. (Pubitemid 30337778)
4. Calabrese LH, Zein N, Vassilopoulos D,. Safety of antitumour necrosis factor (anti-TNF) therapy in patients with chronic viral infections: hepatitis C, hepatitis B, and HIV infection. Ann Rheum Dis 2004; 63 (Suppl. II): 18-24.
5. Pathirana D, Ormerod AD, Saiaj P, et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009; 23 (Suppl. 2): S1-S70.
6. Caroll MB, Bond ML,. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. Semin Arthritis Rheum 2008; 38: 208-217.
7. Calabrese LH, Zein N, Vassilopoulos D,. Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies. Ann Rheum Dis 2006; 65: 983-989. (Pubitemid 44133258)
8. Kuroda T, Wada Y, Kobayashi D, et al. Effect of etanercept and entecavir in a patient with rheumatoid arthritis who is a hepatitis B carrier: a review of the literature. Rheumatol Int 2010, doi:.
9. Li S, Kaur PP, Chan V, Berney S,. Use of tumor necrosis factor-a (TNF-a) antagonists infliximab, etanercept and adalimumab in patients with concurrent rheumatoid arthritis and hepatitis B or hepatitis C: a retrospective record review of 11 patients. Clin Rheumatol 2009; 28: 787-791.
10. Chung SJ, Kim JK, Park MC, et al. Reactivation of hepatitis B viral infection in inactive HBsAg carriers following anti-tumor necrosis factor-alpha therapy. J Rheumatol 2009; 36: 2416-2420.
11. Wendling D, Di Martino V, Prati C, et al. Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine 2009; 76: 308-311.
12. Conde-Taboada A, Pedraz Munoz J, Campos Munoz L, Lopez-Braun E,. Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection. J Am Acad Dermatol 2009; 60: 1076-1077.
13. Cansu DU, Kalifoglou T, Korkmaz C,. Short-term course of chronic hepatitis B and C under treatment with etanercept associated different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008; 35: 421-424. (Pubitemid 351374414)
14. Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008; 28: 718-720.
15. Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondyloarthropathies with concurrent B or C chronic hepatitis. Rheumatology 2006; 45: 1294-1297. (Pubitemid 44542073)
16. Esteve M, Saro C, Gonzalez-Huix F, Suarez F, Forne M, Viver JM,. Chronic hepatitis B reactivation following infliximab therapy in Crohns disease patients: need for primary prophylaxis. Gut 2004; 53: 1363-1365. (Pubitemid 39120128)
17. Michel M, Duvoux C, Hezode C, Cherqui D,. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset Stills disease. J Rheumatol 2003; 30: 1624-1625. (Pubitemid 36835467)
18. Domm S, Cinati J, Mrowietz U,. The impact of treatment with tumour necrosis factor-a antagonists on the course of chronic viral infections: a review of the literature. Br J Dermatol 2008; 159: 1217-1228.
19. Kalyoncu U, Yonem O, Calguneri M, et al. Prophylactic use of lamivudine with chronic immunosuppressive therapy for rheumatologic disorders. Rheumatol Int 2009; 29: 777-780.
20. Papatheodoridis GV, Manesis EK, Manolakopoulos S, et al. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen negative chronic hepatitis B virus infection? Hepatology 2008; 48: 1451-1459.